SEARCH

SEARCH BY CITATION

References

  • Anders A., Gilbert S., Garten W., Postina R. and Fahrenholz F. (2001) Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 15, 18371839.
  • Arduise C., Abache T., Li L., Billard M., Chabanon A., Ludwig A., Mauduit P., Boucheix C., Rubinstein E. and Le N. F. (2008) Tetraspanins regulate ADAM10-mediated cleavage of TNF-alpha and epidermal growth factor. J. Immunol. 181, 70027013.
  • Bai S., Nasser M. W., Wang B., Hsu S. H., Datta J., Kutay H., Yadav A., Nuovo G., Kumar P. and Ghoshal K. (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J. Biol. Chem. 284, 3201532027.
  • Baker A. H., Edwards D. R. and Murphy G. (2002) Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115, 37193727.
  • Born J., Lange T., Kern W., McGregor G. P., Bickel U. and Fehm H. L. (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat. Neurosci. 5, 514516.
  • Buxbaum J. D., Oishi M., Chen H. I., Pinkas-Kramarski R., Jaffe E. A., Gandy S. E. and Greengard P. (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. Proc. Natl. Acad. Sci. USA 89, 1007510078.
  • Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A. and LaFerla F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671682.
  • Cachard-Chastel M., Lezoualc’h F., Dewachter I., Delomenie C., Croes S., Devijver H., Langlois M., van Leuven F., Sicsic S. and Gardier A. M. (2007) 5-HT4 receptor agonists increase sAPPalpha levels in the cortex and hippocampus of male C57BL/6j mice. Br. J. Pharmacol. 150, 883892.
  • Carr G. V., Schechter L. E. and Lucki I. (2011) Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology (Berl) 213, 499507.
  • Chen C. D., Podvin S., Gillespie E., Leeman S. E. and Abraham C. R. (2007) Insulin stimulates the cleavage and release of the extracellular domain of Klotho by ADAM10 and ADAM17. Proc. Natl. Acad. Sci. U S A 104, 1979619801.
  • Czech C., Forstl H., Hentschel F., Monning U., Besthorn C., Geiger-Kabisch C., Sattel H., Masters C. and Beyreuther K. (1994) Apolipoprotein E-4 gene dose in clinically diagnosed Alzheimer’s disease: prevalence, plasma cholesterol levels and cerebrovascular change. Eur. Arch. Psychiatry Clin. Neurosci. 243, 291292.
  • Davis A. A., Fritz J. J., Wess J., Lah J. J. and Levey A. I. (2010) Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci. 30, 41904196.
  • Dawson L. A., Nguyen H. Q. and Li P. (2001) The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 25, 662668.
  • Deane R., Du Y. S., Submamaryan R. K. et al. (2003) RAGE mediates amyloid-beta peptide transport across the blood–brain barrier and accumulation in brain. Nat. Med. 9, 907913.
  • Diaz-Rodriguez E., Montero J. C., Esparis-Ogando A., Yuste L. and Pandiella A. (2002) Extracellular signal-regulated kinase phosphorylates tumor necrosis factor alpha-converting enzyme at threonine 735: a potential role in regulated shedding. Mol. Biol. Cell 13, 20312044.
  • Donmez G., Wang D., Cohen D. E. and Guarente L. (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142, 320332.
  • Etcheberrigaray R., Tan M., Dewachter I. et al. (2004) Therapeutic effects of PKC activators in Alzheimer’s disease transgenic mice. Proc. Natl. Acad. Sci. USA 101, 1114111146.
  • Fassbender K., Simons M., Bergmann C. et al. (2001) Simvastatin strongly reduces levels of Alzheimer’s disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U S A 98, 58565861.
  • Hanson L. R. and Frey W. H. (2007) Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. J. Neuroimmune Pharmacol. 2, 8186.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Holz G. G., Kang G., Harbeck M., Roe M. W. and Chepurny O. G. (2006) Cell physiology of cAMP sensor Epac. J. Physiol. 577, 515.
  • Hongpaisan J., Sun M. K. and Alkon D. L. (2011) PKC epsilon activation prevents synaptic loss, Abeta elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J. Neurosci. 31, 630643.
  • Hopkins A. L. and Groom C. R. (2002) The druggable genome. Nat. Rev. Drug Discov. 1, 727730.
  • Horiuchi K., Le Gall S., Schulte M., Yamaguchi T., Reiss K., Murphy G., Toyama Y., Hartmann D., Saftig P. and Blobel C. P. (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell 18, 176188.
  • Hundhausen C., Schulte A., Schulz B. et al. (2007) Regulated shedding of transmembrane chemokines by the disintegrin and metalloproteinase 10 facilitates detachment of adherent leukocytes. J. Immunol. 178, 80648072.
  • Hung A. Y., Haass C., Nitsch R. M., Qiu W. Q., Citron M., Wurtman R. J., Growdon J. H. and Selkoe D. J. (1993) Activation of protein kinase C inhibits cellular production of the amyloid beta-protein. J. Biol. Chem. 268, 2295922962.
  • Jarvik G. P., Wijsman E. M., Kukull W. A., Schellenberg G. D., Yu C. and Larson E. B. (1995) Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer’s disease: a case-control study. Neurology 45, 10921096.
  • Joyal J. L., Burks D. J., Pons S., Matter W. F., Vlahos C. J., White M. F. and Sacks D. B. (1997) Calmodulin activates phosphatidylinositol 3-kinase. J. Biol. Chem. 272, 2818328186.
  • Karuppagounder S. S., Pinto J. T., Xu H., Chen H. L., Beal M. F. and Gibson G. E. (2009) Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int. 54, 111118.
  • Kim S. H., Fraser P. E., Westaway D., St George-Hyslop P. H., Ehrlich M. E. and Gandy S. (2010) Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer’s amyloid(beta)42 from isolated intact nerve terminals. J. Neurosci. 30, 38703875.
  • Kohen R., Metcalf M. A., Khan N., Druck T., Huebner K., Lachowicz J. E., Meltzer H. Y., Sibley D. R., Roth B. L. and Hamblin M. W. (1996) Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J. Neurochem. 66, 4756.
  • Kojro E. and Postina R. (2009) Regulated proteolysis of RAGE and AbetaPP as possible link between type 2 diabetes mellitus and Alzheimer’s disease. J. Alzheimers Dis. 16, 865878.
  • Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl. Acad. Sci. USA 98, 58155820.
  • Kojro E., Postina R., Buro C., Meiringer C., Gehrig-Burger K. and Fahrenholz F. (2006) The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 20, 512514.
  • Kojro E., Fuger P., Prinzen C., Kanarek A. M., Rat D., Endres K., Fahrenholz F. and Postina R. (2010) Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis. J. Alzheimers Dis. 20, 12151231.
  • Kovacs D. M., Wasco W., Witherby J., Felsenstein K. M., Brunel F., Roeder R. G. and Tanzi R. E. (1995) The upstream stimulatory factor functionally interacts with the Alzheimer amyloid beta-protein precursor gene. Hum. Mol. Genet. 4, 15271533.
  • Lammich S., Buell D., Zilow S., Ludwig A. K., Nuscher B., Lichtenthaler S. F., Prinzen C., Fahrenholz F. and Haass C. (2010) Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5’-untranslated region. J. Biol. Chem. 285, 1575315760.
  • Lannfelt L., Basun H., Wahlund L. O., Rowe B. A. and Wagner S. L. (1995) Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer’s disease. Nat. Med. 1, 829832.
  • Le Gall S. M., Bobe P., Reiss K., Horiuchi K., Niu X. D., Lundell D., Gibb D. R., Conrad D., Saftig P. and Blobel C. P. (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol. Biol. Cell 20, 17851794.
  • Lee R. K., Wurtman R. J., Cox A. J. and Nitsch R. M. (1995) Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc. Natl. Acad. Sci. USA 92, 80838087.
  • Lee B. Y., Ban J. Y. and Seong Y. H. (2005) Chronic stimulation of GABAA receptor with muscimol reduces amyloid beta protein (25-35)-induced neurotoxicity in cultured rat cortical cells. Neurosci. Res. 52, 347356.
  • Lehtonen A. and Luutonen S. (1986) High-density lipoprotein cholesterol levels of very old people in the diagnosis of dementia. Age Ageing 15, 267270.
  • Little K. D., Hemler M. E. and Stipp C. S. (2004) Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpha q/11 association. Mol. Biol. Cell 15, 23752387.
  • Lorke D. E., Lu G., Cho E. and Yew D. T. (2006) Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients. BMC Neurosci. 7, 36.
  • Louzada P. R., Paula Lima A. C., Mendonca-Silva D. L., Noel F., De Mello F. G. and Ferreira S. T. (2004) Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer’s disease and other neurological disorders. FASEB J. 18, 511518.
  • Mackic J. B., Stins M., McComb J. G. et al. (1998) Human blood-brain barrier receptors for Alzheimer’s amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J. Clin. Invest. 102, 734743.
  • Mackic J. B., Bading J., Ghiso J., Walker L., Wisniewski T., Frangione B. and Zlokovic B. V. (2002) Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer’s disease lesions. Vasc. Pharmacol. 38, 303313.
  • Maillet M., Robert S. J., Cacquevel M., Gastineau M., Vivien D., Bertoglio J., Zugaza J. L., Fischmeister R. and Lezoualc’h F. (2003) Crosstalk between Rap1 and Rac regulates secretion of sAPPalpha. Nat. Cell Biol. 5, 633639.
  • Majumdar G., Harrington A., Hungerford J., Martinez-Hernandez A., Gerling I. C., Raghow R. and Solomon S. (2006) Insulin dynamically regulates calmodulin gene expression by sequential o-glycosylation and phosphorylation of sp1 and its subcellular compartmentalization in liver cells. J. Biol. Chem. 281, 36423650.
  • Marcade M., Bourdin J., Loiseau N., Peillon H., Rayer A., Drouin D., Schweighoffer F. and Desire L. (2008) Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106, 392404.
  • Marcello E., Gardoni F., Di L. M. and Perez-Otano I. (2010) An arginine stretch limits ADAM10 exit from the endoplasmic reticulum. J. Biol. Chem. 285, 1037610384.
  • Moss M. L., Bomar M., Liu Q. et al. (2007) The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events. J. Biol. Chem. 282, 3571235721.
  • Muraguchi T., Takegami Y., Ohtsuka T. et al. (2007) RECK modulates Notch signaling during cortical neurogenesis by regulating ADAM10 activity. Nat. Neurosci. 10, 838845.
  • Nitsch R. M., Slack B. E., Wurtman R. J. and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304307.
  • Nitsch R. M., Deng M., Growdon J. H. and Wurtman R. J. (1996) Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. J. Biol. Chem. 271, 41884194.
  • Ohtsu H., Dempsey P. J. and Eguchi S. (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am. J. Physiol. Cell Physiol. 291, C110.
  • Pettit G. R., Herald C. L., Doubek D. L., Herald D. L., Arnold E. and Clardy J. (1982) Isolation and structure of bryostatin 1. J. Am. Chem. Soc. 104, 68466848.
  • Prinzen C., Muller U., Endres K., Fahrenholz F. and Postina R. (2005) Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J. 19, 15221524.
  • Qin W., Chachich M., Lane M. et al. (2006) Calorie restriction attenuates Alzheimer’s disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis. 10, 417422.
  • Querfurth H. W., Jiang J., Xia W. and Selkoe D. J. (1999) Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter. Gene 232, 125141.
  • Rat D., Schmitt U., Tippmann F., Dewachter I., Theunis C., Wieczerzak E., Postina R., van Leuven F., Fahrenholz F. and Kojro E. (2011) Neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) slows down Alzheimer’s disease-like pathology in amyloid precursor protein-transgenic mice. FASEB J. 25, 32083218.
  • Refolo L. M., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G. S., Sambamurti K., Duff K. and Pappolla M. A. (2000) Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7, 321331.
  • Reger M. A., Watson G. S., Green P. S. et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70, 440448.
  • Reiss K., Cornelsen I., Husmann M., Gimpl G. and Bhakdi S. (2011) Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. J. Biol. Chem. 286, 2693126942.
  • Richard T., Pawlus A. D., Iglesias M. L., Pedrot E., Waffo-Teguo P., Merillon J. M. and Monti J. P. (2011) Neuroprotective properties of resveratrol and derivatives. Ann. N Y Acad. Sci. 1215, 103108.
  • Robert S. J., Zugaza J. L., Fischmeister R., Gardier A. M. and Lezoualc’h F. (2001) The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. J. Biol. Chem. 276, 4488144888.
  • Schechter L. E., Lin Q., Smith D. L. et al. (2008) Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466. Neuropsychopharmacology 33, 13231335.
  • Schliebs R. and Arendt T. (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer’s disease. J. Neural Transm. 113, 16251644.
  • Schulz B., Pruessmeyer J., Maretzky T., Ludwig A., Blobel C. P., Saftig P. and Reiss K. (2008) ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin. Circ. Res. 102, 11921201.
  • Sennvik K., Fastbom J., Blomberg M., Wahlund L. O., Winblad B. and Benedikz E. (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 278, 169172.
  • Solano D. C., Sironi M., Bonfini C., Solerte S. B., Govoni S. and Racchi M. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J. 14, 10151022.
  • Sparks D. L., Kuo Y. M., Roher A., Martin T. and Lukas R. J. (2000) Alterations of Alzheimer’s disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann. N Y Acad. Sci. 903, 335344.
  • Spengler D., Waeber C., Pantaloni C., Holsboer F., Bockaert J., Seeburg P. H. and Journot L. (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature 365, 170175.
  • Stein M. S., Scherer S. C., Ladd K. S. and Harrison L. C. (2011) A Randomized Controlled Trial of High-Dose Vitamin D2 Followed by Intranasal Insulin in Alzheimer’s Disease. J. Alzheimers. Dis. 26, 477484.
  • Sun M. K. and Alkon D. L. (2005) Dual effects of bryostatin-1 on spatial memory and depression. Eur. J. Pharmacol. 512, 4351.
  • Thathiah A. and De Strooper B. (2011) The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. Nat. Rev. Neurosci. 12, 7387.
  • Tippmann F., Hundt J., Schneider A., Endres K. and Fahrenholz F. (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23, 16431654.
  • Uchida D., Arimura A., Somogyvari-Vigh A., Shioda S. and Banks W. A. (1996) Prevention of ischemia-induced death of hippocampal neurons by pituitary adenylate cyclase activating polypeptide. Brain Res. 736, 280286.
  • Vaudry D., Falluel-Morel A., Bourgault S. et al. (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 61, 283357.
  • Wang D. and Sul H. S. (1997) Upstream stimulatory factor binding to the E-box at -65 is required for insulin regulation of the fatty acid synthase promoter. J. Biol. Chem. 272, 2636726374.
  • Wu Z. L., Ciallella J. R., Flood D. G., O’Kane T. M., Bozyczko-Coyne D. and Savage M. J. (2006) Comparative analysis of cortical gene expression in mouse models of Alzheimer’s disease. Neurobiol. Aging 27, 377386.
  • Xu D., Sharma C. and Hemler M. E. (2009) Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J. 23, 36743681.
  • Yanez-Mo M., Barreiro O., Gordon-Alonso M., Sala-Valdes M. and Sanchez-Madrid F. (2009) Tetraspanin-enriched microdomains: a functional unit in cell plasma membranes. Trends Cell Biol. 19, 434446.
  • Yanez-Mo M., Gutierrez-Lopez M. D. and Cabanas C. (2011) Functional interplay between tetraspanins and proteases. Cell. Mol. Life Sci. 68, 33233335.
  • Zhang X., Zhang R., Zhao H., Cai H., Gush K. A., Kerr R. G., Pettit G. R. and Kraft A. S. (1996) Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 56, 802808.
  • Zhang L., Bukulin M., Kojro E., Roth A., Metz V. V., Fahrenholz F., Nawroth P. P., Bierhaus A. and Postina R. (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J. Biol. Chem. 283, 3550735516.